|
N/A
|
ACN12001-001
|
$270
|
-, -
|
NASA/JPL JET PROPULSION LABORA
|
|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
5R21CA208736-02
|
$180,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
5R01CA216248-02
|
$607,904
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
(9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics
|
5R01CA215802-02
|
$511,546
|
SPARREBOOM, ALEXANDER
|
OHIO STATE UNIVERSITY
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
5R01CA216290-02
|
$309,819
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ 5) Roles of mitochondrial heterogeneity in cell survival and oncogenesis
|
5R21CA216304-02
|
$195,750
|
NEWMEYER, DONALD
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
5R01CA205965-02
|
$640,839
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy
|
5R21CA215985-02
|
$165,000
|
CHANG, KAREN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-03
|
$630,724
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ1) Cellular senescence as an initiating event in malignant transformation
|
5R21CA206013-02
|
$169,500
|
DAVID, GREGORY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal Cancers
|
5R01CA205258-03
|
$464,261
|
GUDAS, LORRAINE
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
|
5R01CA205954-03
|
$703,249
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
5R01CA206026-03
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ1) Identifying and targeting human glioblastoma migrating in the peritumoral niche
|
5R01CA216054-02
|
$324,411
|
HAYDEN GEPHART, MELANIE
|
STANFORD UNIVERSITY
|
|
(PQ1) Lipid Metabolism, Inflammation, and T cell Dysfunction in HIV-associated Cancer
|
5R01CA206483-02
|
$570,958
|
EMU, BRINDA
|
YALE UNIVERSITY
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-03
|
$706,386
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer
|
5R01CA206010-03
|
$369,639
|
CARETHERS, JOHN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
(PQ5) Consequences of imbalanced mitophagy and mitochondrial biogenesis in cancer
|
5R01CA216242-02
|
$319,238
|
MACLEOD, KAY
|
UNIVERSITY OF CHICAGO
|
|
(PQ5) Effect of HIV infection on viral and host gene expression and antitumor immunity in Kaposi Sarcoma in Africa
|
5R01CA217138-02
|
$723,817
|
WARREN, EDUS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
5R01CA205967-03
|
$386,588
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition
|
5R01CA206012-03
|
$403,884
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ5) Role of Mitochondrial Division in Cancer Biology
|
5R01CA206005-03
|
$351,209
|
CHIPUK, JERRY
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
|
5R01CA205632-03
|
$457,974
|
RIEGEL, ANNA
|
GEORGETOWN UNIVERSITY
|
|
(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment
|
5R01CA205431-03
|
$522,325
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
5R01CA216273-02
|
$740,321
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy
|
5R01CA206028-03
|
$342,846
|
GEWIRTZ, DAVID
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
5R01CA205255-03
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy
|
5R01CA205166-02
|
$537,592
|
KELLEY, MARK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQA4) Molecularly Targeted Chemoprevention for Preneoplastic Squamous (5R01 CA194617-02)
|
5R01CA194617-05
|
$382,108
|
TSAI, KENNETH
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
(PQA5) Dose and Mechanisms of Exercise in Breast Cancer Prevention
|
5R01CA179992-05
|
$648,503
|
JONES, LEE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
(PQC1) Accelerated biological aging and colon polyp to cancer progression
|
5R01CA194663-04
|
$401,448
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQC2) Localization as a determinant of cancer dormancy
|
5R01CA194596-04
|
$525,066
|
LIN, CHARLES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
(PQD-3) Spatiotemporal Molecular Interrogation of Early Metastatic Evolution In Situ
|
5R01CA194697-04
|
$347,700
|
ZHANG, SIYUAN
|
UNIVERSITY OF NOTRE DAME
|
|
00005I-0140 NCI-OD -- 8422873
|
271201800005I
|
$43,698
|
N/A
|
KELLY SERVICES INC
|
|
00007I-4739 NCI-OD -- 8422873
|
271201500007I
|
$24,553
|
N/A
|
KELLY SERVICES INC
|
|
00012I-0329 NCI-OD -- 8422873
|
271201800012I
|
$137,572
|
N/A
|
KELLY SERVICES INC
|
|
01/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048377-25
|
$39,000
|
GADDE, KISHORE
|
LSU PENNINGTON BIOMEDICAL RESEARCH CTR
|
|
02/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048381-25
|
$68,181
|
EHRMANN, DAVID
|
UNIVERSITY OF CHICAGO
|
|
03/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048468-25
|
$68,181
|
FURLONG, KEVIN
|
THOMAS JEFFERSON UNIVERSITY
|
|
04/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048434-25
|
$68,181
|
GOLDBERG, RONALD
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
05/22 Diabetes Prevention Program Outcomes Study (DPPOS) - Phase 3 - Research Project
|
5U01DK048514-25
|
$68,181
|
HAZUDA, HELEN
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
06/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048375-25
|
$68,181
|
DABELEA, DANA
|
UNIVERSITY OF COLORADO DENVER
|
|
07/22 Diabetes Prevention Program Outcomes Study (DPPOS)Phase 3 - Research Project
|
5U01DK048437-25
|
$42,300
|
MUNSHI, MEDHA
|
JOSLIN DIABETES CENTER
|
|
08/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048413-25
|
$68,181
|
KAHN, STEVEN
|
SEATTLE INST FOR BIOMEDICAL/CLINICAL RES
|
|
09/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048411-25
|
$58,181
|
DAGOGO-JACK, SAMUEL
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
10/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3- Research Project
|
5U01DK048380-25
|
$68,181
|
MOLITCH, MARK
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
11/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048397-25
|
$68,181
|
NATHAN, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
13/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048404-25
|
$68,181
|
PI-SUNYER, XAVIER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
14/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048406-25
|
$68,181
|
MATHER, KIEREN
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
15-LOX-1 Modulation of Colon Cancer Promotion by Linoleic Acid
|
5R01CA206539-03
|
$366,000
|
SHUREIQI, IMAD
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|